Market research
PRTK Paratek Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 2.15
- Dividend yield
- 0.0%
- Beta
- 1.7
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6993743029
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 2.15
- Dividend yield
- 0.0%
- Beta
- 1.7
About
About Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRTK discussion.
5 years, 4 months ago
Paratek Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 5.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Paratek Pharmaceuticals, Inc's total revenue rose by 78.6% to $16M since the same quarter in the previous year.
Its net income has increased by 8.6% to $-25M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-24M since the same quarter in the previous year.
Based on the above factors, Paratek Pharmaceuticals, Inc gets an overall score of 4/5.